Navigation Links
Ulthera Appoints Greg Waller as Chief Financial Officer
Date:12/6/2011

MESA, Ariz., Dec. 6, 2011 /PRNewswire/ -- Ulthera, Inc. – a global, commercial-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology –  today announced that it has named Greg Waller as Chief Financial Officer (CFO), a newly created position at Ulthera.

(Photo: http://photos.prnewswire.com/prnh/20111206/NY17456-a)

(Photo: http://photos.prnewswire.com/prnh/20111206/NY17456LOGO-b)

"Greg's results-oriented skillset will play a vital role in further enhancing our sound corporate infrastructure as more and more cosmetic physicians in the U.S. and internationally adopt our device to help meet the ever-growing consumer demand for safe and effective non-invasive procedures," said Matthew Likens, president and CEO of Ulthera. "I am confident that Greg will provide steadfast leadership to ensure a strong financial future for our growing company, especially as we tap the potential of our platform technology."

Waller's three-and-a-half decades of experience showcases a solid track record of strategic financial growth for both privately held and publically traded companies. Most recently, Waller served as CFO of Universal Building Products, a manufacturer of concrete construction accessories. Prior to that, he held several leadership positions at Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products. During his 25-year tenure with Sybron, he was instrumental in the IPO of the company and in more than 30 company acquisitions worldwide. He also played a pivotal role in supporting the growth of the company from 100 to more than 4,000 employees and from $10 million to more than $750 million in sales.

Waller currently serves as a board member and audit committee chairman for Endologix, Inc. and as a board member for Sunshine Heart, Inc. Additionally, he previously served as board member and audit committee chairman for Alsius, Inc., Biolase, Inc., Cardiogenesis Inc., Clarient, Inc. and SenoRx, Inc., all publicly traded companies.

"Although a young company, the technology achievements, market penetration and clinical respect that Ulthera has garnered in such a short period of time is not only impressive and significant; it is an auspicious indicator of what's to come," stated Waller. "I am honored to be part of such a promising company where medical innovation is highly encouraged, and consistency, safety and efficacy are at the heart of operating principals."

About Ulthera

Ulthera®, Inc. is a global, commercial-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive face and neck treatment to achieve a brow lift. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company backed by top tier venture capital firms, New Enterprise Associates and Apposite Capital. For more information, visit www.ulthera.com


'/>"/>
SOURCE Ulthera
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ulthera Announces $10.5 Million in Series C Venture Capital Funding
2. Ulthera CEO - Matthew Likens - to Present at Two Upcoming Healthcare Conferences
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. West Pharmaceutical Services, Inc. Appoints New Director
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Curemark Appoints Preeminent Pediatrics Gastroenterologist
7. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
10. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
11. NovaRx Appoints Industry Veteran as President and COO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):